TokenPost·
Foghorn Therapeutics Posts $0.80 Q3 GAAP EPS, $83.5 Million Revenue
Research and development expenses fell $1.2 million from a year earlier.
More news
- TokenPostStrategy Repurchases $188.3 Million in STRC Preferred Shares
- The DefiantEthlabs Urges Glamsterdam Hold Pending Audit Findings
- TokenPostQumulusAI Secures 1.2 MW of Denver Colocation Capacity for AI Cloud
- TokenPostJPMorgan Downgrades Molson Coors as U.S. Beer Trends Stay Weak
- TokenPostSharplink's Ether Gains Drive $751.4 Million Third-Quarter Profit
- crypto.newsTrump Media adds 1,510 Bitcoin in Q3 as treasury reaches $1.17B